1stOncology™: Cancer Intelligence Service – Page 8942 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II Study of Novel Radiosensitizer for Cancer Radiotherapy

On July 29, 2021 KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), reported the closing of an equity investment from AXA Japan (Press release, KORTUC, JUL 29, 2021, View Source [SID1234585478]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US. Currently ongoing Pivotal Phase II Study focuses on application of Kortuc radiosensitizer to locally advanced/recurrent breast cancer patients undergoing RT.

Comments from KORTUC
"We are pleased to share our vision with and receive such strong support from our new investor as we are accelerating our clinical research in the UK and the US to bring to cancer patients globally a product that can make a true difference in the near future – we firmly believe that Kortuc radiosensitizer can change the paradigm for use of radiotherapy across cancer types and stages" highlighted Kazu Matsuda, Chief Executive Officer of KORTUC.

Comments from AXA Japan
"As a worldwide leader in insurance and asset management, our purpose is to act for human progress by protecting what matters. As new cancer patient growth accelerates, this investment illustrates our purpose to support innovative technologies that can serve humanity." Jean-Baptiste Tricot, Director, Executive Officer and Chief Financial Officer of AXA Japan commented.
Boris Moutier, Corporate Officer of AXA Japan, Japan and Asia Chief Investment Officer, also highlights that "With this brand new radiosensitizer, KORTUC has great potential to become a ground-breaking player in cancer treatment field, and we are glad to engage in this greatly promising journey. Aligned with AXA Group’s vision, AXA Japan pursues investments into startups that may create innovations and produce tangible results."

Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast

On July 29, 2021 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, reported that the Company has scheduled the release of its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021 (Press release, Sangamo Therapeutics, JUL 29, 2021, View Source [SID1234585475]). The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates.

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 1971045. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 1971045.

PROTHENA TO REPORT SECOND QUARTER 2021 FINANCIAL RESULTS ON AUGUST 5TH

On July 29, 2021 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, reported that it will report its second quarter and first six months of 2021 financial results on Thursday, August 5, 2021 after the close of the U.S. financial markets (Press release, Prothena, JUL 29, 2021, View Source [SID1234585474]).

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 5.

Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021

On July 29, 2021 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) reported that it will report its financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021, after the close of the U.S. financial markets (Press release, Y-mAbs Therapeutics, JUL 29, 2021, View Source [SID1234585473]). The announcement will be followed by a conference call and webcast with the investment community on Friday, August 6, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.

Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators – Indivior Commits $4 Million of New Funding

On July 29, 2021 Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported that it has extended its research collaboration agreement with Indivior PLC (LON: INDV) (Press release, Addex Therapeutics, JUL 29, 2021, View Source [SID1234585453]). As part of the extension, Indivior has committed $4 million of new funding to advance development of selected novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates discovered by Addex. The new funding will be used to prepare drug candidates for both Indivior’s substance use disorder program and Addex’s proprietary Charcot-Marie-Tooth type 1A neuropathy program, which are both expected to start IND enabling studies in 2022.

"This additional committed research funding, which will be used to prepare lead drug candidates for IND enabling studies, demonstrates the quality of Addex’s drug discovery platform and the significant achievements made in our Indivor collaboration," said Tim Dyer, CEO of Addex. "In addition, we have seen great progress in the rest of our portfolio, including dipraglurant entering a pivotal study in PD-LID and our partner, Janssen, advancing ADX71149 into a Phase 2a POC for epilepsy."

"Excellent progress has been made in our research collaboration with Addex," said Christian Heidbreder, Chief Scientific Officer of Indivior. "With this new funding, Indivior has reiterated its commitment to advance this novel allosteric approach towards clinical evaluation. The Addex collaboration forms part of our continued strategy of finding novel therapeutic approaches to treat the serious and growing need of people suffering with substance use disorders."

About GABAB Activation with PAM

Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR, is clinically & commercially validated. The generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and used for overactive bladder (OAB), but it is not commonly used due to a variety of side effects and rapid clearance. Potent, selective oral positive allosteric modulators (PAM) that potentiate GABA responses at the GABAB receptor, rather than an orthosteric agonist at the GABAB receptor like baclofen, only act when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and could lead to less tolerance than direct agonists (May and Christopoulos 2003; Langmead and Christopoulos 2006; Perdona et al. 2011; Urwyler 2011; Gjoni et al., 2008; Ahnaou et al).